Asset Details
Do you wish to reserve the book?
Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer
Do you wish to request the book?
Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer
1996
Overview
Ovarian cancer, the leading cause of death from gynecologic cancer in the United States, is one of the few solid tumors in which the five-year survival rate for patients has improved in recent years.
1
,
2
Nevertheless, most women with advanced ovarian cancer die of the disease. Even those with stage III cancer and minimal residual intraperitoneal masses (<2 cm in the greatest dimension) have a median survival of only about 40 months.
3
,
4
Standard chemotherapy for advanced ovarian cancer includes a platinum analogue (either cisplatin or carboplatin). In an attempt to maximize its activity against ovarian cancer, cisplatin has been . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Antineoplastic Combined Chemotherapy Protocols - administration & dosage
/ Antineoplastic Combined Chemotherapy Protocols - adverse effects
/ Biological and medical sciences
/ Cisplatin - administration & dosage
/ Cyclophosphamide - administration & dosage
/ Female
/ Hearing Disorders - chemically induced
/ Humans
/ Leukopenia - chemically induced
/ Oncology
/ Ovarian Neoplasms - drug therapy
/ Ovarian Neoplasms - mortality
/ Ovarian Neoplasms - pathology
